Comparative Pharmacology
Head-to-head clinical analysis: JENLOGA versus OVRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JENLOGA versus OVRAL.
JENLOGA vs OVRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
OVRAL is a combination oral contraceptive containing ethinyl estradiol and norgestrel. It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus, reducing follicle-stimulating hormone (FSH) and luteinizing hormone (LH) release from the pituitary. Additionally, it increases cervical mucus viscosity and alters endometrial receptivity, impeding sperm penetration and implantation.
350 mg orally once daily with food.
One tablet (norgestrel 0.3 mg with ethinyl estradiol 0.03 mg) orally once daily for 21 days followed by 7 days of placebo.
None Documented
None Documented
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (CrCl 30-50 mL/min)
Norgestrel: 24–32 hours; Ethinyl estradiol: 12–18 hours; steady-state achieved after 5–7 days
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal (60% as metabolites, ~40% unchanged); biliary/fecal (40%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive